We found that DNJ targeted nuclear-encoded OPA1 to function as a mitochondrial rescue agent, showing the therapeutic potential of our mitochondrial hypertrophic cardiomyopathy and even other mitochondrial diseases, such as hearing loss, mitochondrial myopathy, or Leigh syndrome. Here, OPA1 is linked to inborn mitochondrial metabolism disorder.